Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2001

View Archived Issues

FDA accepts Estrasorb NDA for review

Vertex and Array BioPharma establish small-molecule drug discovery agreement

Joint Onco TCS clinical development program expanded

Results presented on CryoLife's cancer treatment drug delivery system

Topiglan development continues to move forward

FDA grants fast track designation for Repligen's secretin

Clinical trial of Cur-61414 commences for treatment of sporadic BCC

A new anxioselective compound --SL-65.1498-- characterized

Orally active DP receptor antagonist prevents allergic inflammation in guinea pigs

FXV-673, a new factor Xa inhibitor, compares favorably to heparin in canine thrombosis model

SAR in a series of glycine derivatives results in discovery of selective hGlyT-1b inhibitor

Proof of concept established in phase II trials for NN-622

Therapeutic vaccine for nicotine addiction enters clinical testing

Cell Genesys completes Calydon acquisition

FDA panel emits positive recommendation for Zevalin

Targeted apoptosis research program at Antisoma expanded by newly acquired rights from NIH

Long-term clinical data favor rosuvastatin over other statins in hypercholesterolemia

Novartis, QLT seek approval for expanded use of Visudyne in E.U.

Amiodarone metabolite has similar long-term electrophysiological effects in dogs

Selective cathepsin K inhibitors synthesized and tested at Roche

Celltech patent reveals alpha4 integrin-inhibitory squaric acid derivatives

Bayer presents new integrin inhibitors, uses and pharmaceutical compositions

Piperidine- and piperazine-based P2X7 receptor antagonists designed at AstraZeneca

Antiscarring PCP inhibitors in the Pfizer pipeline

Novuspharma antitumor agents particularly effective against solid tumors

LGD-2226 selected as clinical candidate SARM

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.